BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) promotes lung adenocarcinoma by interacting with Zinc Finger Protein ZNF143 and regulating glycolysis

Zhou, Xiaolei; Yuan, Yifang; Kuang, Hongping; Bingxiang, Tang; Zhang, Hui; Zhang, Manlin

doi:10.1080/21655979.2021.2013108

Cited by 14 publications

(10 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effect of BUB1/3 on the incidence and development of LUAD is not well understood. BUB1B, in conjunction with ZNF143, regulates glycolysis in LUAD, and overexpression of BUB1B had increases the proliferation, migration, and invasion of LUAD cells [ 23 ]. To the best of our knowledge, this is the first study to explore the patterns of expression and prognostic value of BUB1/3 in LUAD.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis of BUBs gene family in lung adenocarcinoma with immunological analysis

Wang

et al. 2023

Aging

View full text Add to dashboard Cite

Lung adenocarcinoma (LUAD) is one of the most commonly malignant tumors, and major challenges remain in the treatment of LUAD. Budding uninhibited by benzimidazole 1/3 (BUB1/3) play significant roles in the process of spindle-assembly checkpoint (SAC) during mitosis. However, their roles in LUAD have not been established. Here, we performed an immunological analysis of BUB1/3 in LUAD using a comprehensive bioinformatics approach, quantitative real-time-PCR and Western blotting technique. Our results indicated that the expression levels of BUB1 and BUB3 in LUAD samples were higher than the expression levels in the control groups and were associated with some clinicopathologic parameters in patients with LUAD. BUB1/3 and their related genes were enriched in cell immune, and the immune infiltration analysis revealed that the BUB1/3 expression profile was significantly correlated with characteristics of immune cell infiltration. Survival analysis showed that the diseasefree survival and overall survival of patients with LUAD decreased with an increase in the BUB1/3 expression levels. The mRNA and protein expression levels of BUB1 and BUB3 in each of the LUAD cell lines were upregulated to varying degrees. BUB1 and BUB3 are the potential immunological therapeutic intervention targets for patients with LUAD.

show abstract

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis of BUBs gene family in lung adenocarcinoma with immunological analysis

Wang

et al. 2023

Aging

View full text Add to dashboard Cite

show abstract

“…Among the all differential genes, we selected one of the candidates, BUB1B for clinical validation. Consistently, a prior investigation demonstrated that BUB1B is overexpressed in lung cancer and is presumed to regulate the development and progression of lung cancer via glycogen metabolism signaling 61 . To better understand the precise role of BUB1B in LUAD immunotherapy, future functional studies should be conducted both in vitro and in vivo.…”

Section: Discussionmentioning

confidence: 69%

“…Consistently, a prior investigation demonstrated that BUB1B is overexpressed in lung cancer and is presumed to regulate the development and progression of lung cancer via glycogen metabolism signaling. 61 To better understand the precise role of BUB1B in LUAD immunotherapy, future functional studies should be conducted both in vitro and in vivo. Moreover, our model has underscored the crucial significance of other genes, specifically forkhead box M1 (FOXM1), cyclin A2 (CCNA2), and cyclin dependent kinase 1 (CDK1).…”

Section: Discussionmentioning

confidence: 99%

Machine learning‐based establishment and validation of age‐related patterns for predicting prognosis in non‐small cell lung cancer within the context of the tumor microenvironment

Ma,

Han,

Zhou

et al. 2023

IUBMB Life

View full text Add to dashboard Cite

Lung cancer (LC) is a leading cause of cancer‐related mortality worldwide, with non‐small cell lung cancer (NSCLC) accounting for over 80% of cases. The impact of aging on clinical outcomes in NSCLC remains poorly understood, particularly with respect to the immune response. In this study, we explored the effects of aging on NSCLC using 307 genes associated with human aging from the Human Ageing Genomic Resources. We identified 53 aging‐associated genes that significantly correlate with overall survival of NSCLC patients, including the clinically validated gene BUB1B. Furthermore, we developed an aging‐associated enrichment score to categorize patients based on their aging subtypes and evaluated their prognostic and therapeutic response values in LC. Our analyses yielded two aging‐associated subtypes with unique profiles in the tumor microenvironment, demonstrating varying responses to immunotherapy. Consensus clustering based on transcriptome profiles provided insights into the effects of aging on NSCLC and highlighted the potential of personalized therapeutic approaches tailored to aging subtypes. Our findings provide a new target and theoretical support for personalized therapeutic approaches in patients with NSCLC, offering insights into the potential impact of aging on cancer outcomes.

show abstract

“…A present metaanalysis showed that high BUB1B expression predicts poor OS and progression-free survival (PFS) and that BUB1B is an important biomarker for poor prognosis and poor clinicopathological outcome in patients with LUAD (27). Zhou et al (28) found that BUB1B was upregulated in LUAD, and clinical survival is shorter in LUAD patients with high BUB1B expression. Expression of CCNB1 is significantly elevated in samples from LUAD patients and is associated with advanced tumor stage and shorter OS (29), and TTK is a mitotic checkpoint kinase that is present in higher amounts in some human cancers than in normal tissue (30).…”

Section: Discussionmentioning

confidence: 77%

“…Zhou et al. ( 28 ) found that BUB1B was upregulated in LUAD, and clinical survival is shorter in LUAD patients with high BUB1B expression. Expression of CCNB1 is significantly elevated in samples from LUAD patients and is associated with advanced tumor stage and shorter OS ( 29 ), and TTK is a mitotic checkpoint kinase that is present in higher amounts in some human cancers than in normal tissue ( 30 ).…”

Section: Discussionmentioning

confidence: 99%

Characteristics of Fatty Acid Metabolism in Lung Adenocarcinoma to Guide Clinical Treatment

et al. 2022

View full text Add to dashboard Cite

BackgroundLung adenocarcinoma (LUAD) has a very high morbidity and mortality rate, and its pathogenesis and treatment are still in the exploratory stage. Fatty acid metabolism plays a significant role in tumorigenesis, progression, and immune regulation. However, the gene expression of fatty acid metabolism in patients with LUAD and its relationship with prognosis remain unclear.MethodsWe collected 309 fatty acid metabolism-related genes, established a LUAD risk model based on The Cancer Genome Atlas (TCGA) using Least Absolute Shrinkage Selection Operator (LASSO) regression analysis, and divided LUAD patients into high-risk and low-risk groups, which were further validated using the Gene Expression Omnibus (GEO) database. The nomogram, principal component analysis (PCA), and receiver operating characteristic (ROC) curves showed that the model had the best predictive performance. The ROC curves and calibration plots confirmed that the nomogram had good predictive power. We further analyzed the differences in clinical characteristics, immune cell infiltration, immune-related functions, chemotherapy drug sensitivity, and immunotherapy efficacy between the high-risk and low-risk groups. We also analyzed the enrichment pathways and protein–protein interaction (PPI) networks of different genes in the high-risk and low-risk groups to screen for target genes and further explored the correlation between target genes and differences in survival prognosis, clinical characteristics, gene mutations, and immune cells.ResultsRisk score and staging are independent prognostic factors for patients with LUAD. The high-risk group had lower immune cell infiltration, was more sensitive to chemotherapeutic agents, and had a poorer survival prognosis. We also obtained three pivotal genes with poor survival prognosis in the high expression group, which were strongly associated with clinical symptoms and immune cells.ConclusionRisk score and staging are independent prognostic factors for patients with LUAD. The high-risk group had lower immune cell infiltration, was more sensitive to chemotherapeutic agents, and had a poorer survival prognosis. We also obtained three survival prognosis-associated target genes that are closely associated with clinical symptoms and immune cells and may be potential targets for immune-targeted therapy in LUAD.

show abstract

BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) promotes lung adenocarcinoma by interacting with Zinc Finger Protein ZNF143 and regulating glycolysis

Cited by 14 publications

References 39 publications

Comprehensive analysis of BUBs gene family in lung adenocarcinoma with immunological analysis

Comprehensive analysis of BUBs gene family in lung adenocarcinoma with immunological analysis

Machine learning‐based establishment and validation of age‐related patterns for predicting prognosis in non‐small cell lung cancer within the context of the tumor microenvironment

Characteristics of Fatty Acid Metabolism in Lung Adenocarcinoma to Guide Clinical Treatment

Contact Info

Product

Resources

About